Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › OUTSTAND-1 (early T2D, monotherapy)

OUTSTAND-1 (early T2D, monotherapy)

HRS-7535 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
HRS-7535
Population
t2d
Official title
A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Phase
3
Registry status
completed · 2024-09 → 2025-11
Participants
284
Duration
32 weeks
Registry
NCT06672172

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
oral HRS-7535 90 mgt2d china32284——−1.7 vs −0.16.9 vs 0.0—————congress
30 mgt2d china32284——−1.4 vs −0.21.4 vs 0.0—————congress
60 mgt2d china32284——−1.4 vs −0.22.9 vs 0.0—————congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (6)
  • oral HRS-7535 90 mg · hba1c · abstract
    reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
  • oral HRS-7535 90 mg · ae_dc · abstract
    mg), and 6.9% (90 mg) versus 0% with pbo in the 32-week period.
  • 30 mg · hba1c · abstract
    reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
  • 30 mg · ae_dc · abstract
    Discontinuation due to AEs occurred in 1.4% (30 mg), 2.9% (60
  • 60 mg · hba1c · abstract
    reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
  • 60 mg · ae_dc · abstract
    Discontinuation due to AEs occurred in 1.4% (30 mg), 2.9% (60

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: OUTSTAND-1 (early T2D, monotherapy). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/outstand-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.